コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 cal specimens from patients with intractable Meniere's disease.
2 an vestibular macula utricle from normal and Meniere's disease.
3 ffort to identify genetic causes of familial Meniere's disease.
4 ated vertigo), bilateral vestibulopathy, and Meniere's disease.
5 s hearing involvement may be misdiagnosed as Meniere's disease.
6 gy as well as the diagnosis and treatment of Meniere's disease.
7 he most debilitating symptom associated with Meniere's disease.
8 sac may be implicated in the pathogenesis of Meniere's disease.
9 will help define the role of vasopressin in Meniere's disease.
10 induced endolymphatic hydrops, a hallmark of Meniere's disease.
11 ablative, effective treatment for refractory Meniere's disease.
12 hwannoma or neurofibromatosis of type 2; (3) Meniere's disease; (4) sudden sensorineural hearing loss
14 the key pathologic finding in patients with Meniere's disease, a disease of episodic vertigo, fluctu
15 es were largest in patients with neuropathy, Meniere's disease and SSNHL, intermediate in the noise-d
16 ntly no cure, more than 85% of patients with Meniere's disease are helped by either changes in lifest
18 like angina pectoris, atrial tachycardia and Meniere's disease, bimatoprost to lentigo maligna melano
29 t association with the clinical diagnosis of Meniere's disease (MD), in two groups of MD patients (n
31 cimens of three different types of patients (Meniere's disease, normal controls, and other otopatholo
32 sterior semicircular canals of patients with Meniere's disease or vestibular schwannoma and measured
33 micin, the standard treatment for refractory Meniere's disease, reduces vertigo, but damages vestibul
35 uch as sudden sensorineural hearing loss and Meniere's disease that are elicited by pathogens and pro
36 aged 18-70 years with refractory unilateral Meniere's disease were enrolled at Charing Cross Hospita
37 2009, and April 15, 2013, 256 patients with Meniere's disease were screened, 60 of whom were enrolle
38 th bilateral IMCVDs or symptoms of bilateral Meniere's disease were treated with etanercept (25 mg tw
39 e GLAST immunoreactive area of patients with Meniere's disease when compared to that of patients with